Please let me know which of these studies you are interested in reading in detail, and I will post;

hopeful and optimistic
hopeful and optimistic Member Posts: 2,333 Member

Prostate Cancer

CUA 2013 - Session Highlights: State-of-the-Art Lecture - Current controversies in prostate cancer management
An educational intervention for patients on androgen deprivation therapy and their partners, "Beyond the Abstract," by Lauren M. Walker, et al.
Bone scan is of doubtful value as a first staging test in the primary presentation of prostate cancer, "Beyond the Abstract," by Lina M. Carmona
Treatment of local-regional prostate cancer detected by PSA screening: Benefits and harms according to prognostic factors - Abstract
Coffee consumption and the risk of prostate cancer: The Ohsaki Cohort Study - Abstract
MR imaging of prostate cancer in radiation oncology: What radiologists need to know - Abstract
Methotrexate therapy leading to a rapid progression of a previously indolent prostate cancer: Is immunosuppression to blame? - Abstract
A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy - Abstract
Outcome of radical prostatectomy in patients meeting criteria for active surveillance - Abstract
Does periprostatic block increase the transrectal ultrasound (TRUS) biopsy sepsis rate in men with elevated PSA? - Abstract
CCL11 (eotaxin-1): A new diagnostic serum marker for prostate cancer, "Beyond the Abstract," by Jill A. Macoska, PhD
Diagnostic and outcome differences between heterosexual and nonheterosexual men treated for prostate cancer - Abstract
Reducing rectal injury during external beam radiotherapy for prostate cancer - Abstract
Agent Orange as a risk factor for high-grade prostate cancer - Abstract
Role of (18)F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer - Abstract
Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer - Abstract
Canadian prostate brachytherapy in 2012 - Abstract
Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists - Abstract
Incremental costs of prostate cancer trials: Are clinical trials really a burden on a public payer system? - Abstract
Metastatic prostate cancer with malignant ascites: A case report and literature review - Abstract
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: Results from a baseline analysis in the Canary Prostate Active Surveillance Study, "Beyond the Abstract," by Lisa Newcomb and Daniel W. Lin
Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy - Abstract
Long-term outcome for prostate cancer using pseudo pulse-dosed rate brachytherapy, external beam radiotherapy, and hormones - Abstract
A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression - Abstract
Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation - Abstract
Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: Oncologic outcomes and morbidity in 1002 patients - Abstract
Breast and prostate cancer survivors in a diabetic cohort: Results from the Living With Diabetes study - Abstract
Technology diffusion and diagnostic testing for prostate cancer - Abstract
Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate (TURP) and correlation with clinical and treatment parameters - Abstract
Hemosepermia after transrectal ultrasound-guided prostatic biopsy: A prospective study - Abstract
Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: A pilot project at a Canadian cancer center - Abstract
Defining high-risk prostate cancer - Abstract
Results of hormone therapy as first-line treatment for high-risk prostate cancer - Abstract
Future prospects: Who is the patient who still dies of prostate cancer following local treatment of high-risk prostate cancer? Can we prolong their lives using modern treatment approaches? - Abstract
Biopsy-proven brain metastases from prostate cancer: A series of four cases with review of the literature - Abstract
Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy (ADT) for prostate cancer - Abstract
MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer - Abstract
Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years - Abstract
"We remain very much the second sex": The constructions of prostate cancer in popular news magazines, 2000-2010 - Abstract
Longitudinal comparison of quality of life after real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer - Abstract
The future of systemic therapies for localised prostate cancer - Abstract
Robot-assisted laparoscopic radical prostatectomy after heart transplantation - Abstract
A review of tasquinimod in the treatment of advanced prostate cancer - Abstract
Patients' perceptions of radical prostatectomy for localized prostate cancer: A qualitative study - Abstract
A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints - Abstract

Advanced Prostate Cancer



AUA 2013 - Poster: Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy
Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy, by Stephen J. Freedland, MD
A current perspective on the use of genomics in the diagnosis and treatment of prostate cancer, an interview with Stephen J. Freedland, MD
Plasma-seq: A novel strategy for metastatic prostate cancer analysis - Abstract


 Bone Metastases

Bone markers for monitoring efficacy in patients with bone metastases receiving zoledronic acid: A review of published data - Abstract

Prostate Cancer Immunotherapy


A message to our readers:

During the past 10 years, UroToday has created – and continues to grow – a truly unique and comprehensive database of urologic content. While we pride ourselves in the ability to provide our readers with free access to over 60,000 pages of content, we now require that all guests be registered and logged on before proceeding to our online resources and archive.

We invite you to take a moment to register. After that, you may simply log on with your user name and password w